TJO-002 is under clinical development by TaeJoon Pharmaceuticals and currently in Phase III for Ocular Hypertension. According to GlobalData, Phase III drugs for Ocular Hypertension have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how TJO-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TJO-002 overview

TJO-002 is under development for the treatment of open-angle glaucoma and ocular hypertension. The drug candidate is administered through ophthalmic route in the form of eye drops.

TaeJoon Pharmaceuticals overview

TaeJoon Pharmaceuticals (Taejoon) is a pharmaceutical company that markets ophthalmic agents and other drugs. It offers products in the form of injections, powders, eye drops, spray, syrups, tablets, soft capsules, liquids for external use, and hard capsules. The company’s powder products comprise of coolprep powder, polyethylen glycol, and colyte powder products. Taejoon’s products are used in ophthalmological, laxative, gastrointestinal, and contrast media applications. It sells products through a network of distributors in South Korea, Thailand, Germany, Russia, the UK and the US. The company operates in Seoul, Gunpo, Daejeon, Daegu, Gwangju and Busan, South Korea. Taejoon is headquartered in Seoul, South Korea.

For a complete picture of TJO-002’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.